# Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

> **NCT00904852** · PHASE1 · WITHDRAWN · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Tandutinib, bevacizumab, and temozolomide

## Key facts

- **NCT ID:** NCT00904852
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-06
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2009-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00904852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00904852, "Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00904852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*